JPMorgan lowered the firm’s price target on Olema Oncology to $28 from $29 and keeps an Overweight rating on the shares. Key changes to the model include expenses and share count, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OLMA:
- Olema Oncology reports Q3 EPS (48c), consensus (51c)
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Olema Oncology to Participate in Upcoming Investor Conferences in November
- Olema Oncology price target raised to $25 from $19 at JPMorgan
- Olema Oncology price target raised to $22 from $16 at Canaccord
